Tuesday, September 09, 2025 5:12:56 PM
ASw,
You’re making up stories & spreading rumors 😶
They did not “pass” on the FDA, and the FDA has approved several DC clinical studies to commence subsequent to the P3. Additionally, the U.S. NIH & U.S. DoD have awarded and renewed peer-reviewed grants for combo research with the DC platforms at Roswell & UCLA.
Anyone can research this for themselves or contact the FDA to ask them…
Fact ✅️:
Demonstrating the ability to consistently manufacture a product at commercial scale is a core requirement for a BLA. The FDA requires sponsors to show they can reliably produce the therapy at the necessary scale with consistent quality & full compliance with Good Manufacturing Practices.
Manufacturing
Ask the FDA:
Division of Industry & Consumer Education (DICE)
1-888-INFO-FDA (1-888-463-6332)
DICE@fda.hhs.gov
Center for Biologics Evaluation & Research (CBER) Customer Service: 1-800-835-4709
CBERCustomerService@fda.hhs.gov
You’re making up stories & spreading rumors 😶
They did not “pass” on the FDA, and the FDA has approved several DC clinical studies to commence subsequent to the P3. Additionally, the U.S. NIH & U.S. DoD have awarded and renewed peer-reviewed grants for combo research with the DC platforms at Roswell & UCLA.
Anyone can research this for themselves or contact the FDA to ask them…
Fact ✅️:
Demonstrating the ability to consistently manufacture a product at commercial scale is a core requirement for a BLA. The FDA requires sponsors to show they can reliably produce the therapy at the necessary scale with consistent quality & full compliance with Good Manufacturing Practices.
Manufacturing
Ask the FDA:
Division of Industry & Consumer Education (DICE)
1-888-INFO-FDA (1-888-463-6332)
DICE@fda.hhs.gov
Center for Biologics Evaluation & Research (CBER) Customer Service: 1-800-835-4709
CBERCustomerService@fda.hhs.gov
Bullish
Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
